Dr. Alexander Hillel's clinical practice and research focuses centers on risk factors for, the prevention of, and treatment for laryngotracheal stenosis (LTS) and other diseases of the trachea and larynx. His laboratory developed robust in vitro and in vivo model systems to study immunologic and metabolic mechanisms promoting laryngotracheal inflammation, airway wall remodeling, and fibrosis to develop new therapies targeting airway disease. Ongoing efforts include applying a novel drug-eluting stent to influence to treat laryngotracheal stenosis. He serves on the leadership team of the North American Airway Collaborative (NoAAC) which is an international organization dedicated to improving our understanding of adult airway disease and developing effective, cost-conscious treatments.
Lab Website: Hillel Laboratory
View all on Pubmed
Murphy MK, Motz K, Ding D, Yin LX, Duvvuri MV, Feeley M, Hillel AT. Targeting metabolic abnormalities to reverse fibrosis in iatrogenic laryngotracheal stenosis. Laryngoscope. 2018;128:E59-67. PMID: 28940431. PMC5771827.
Ma G, Samad I, Ding D, Namba DR, Elisseeff JH, Horton MR, Hillel AT. Metabolic variations in normal and fibrotic human laryngotracheal derived fibroblasts in vitro. Laryngoscope. 2017;127:E107-13. PMID: 27585358. PMC5321789.
Gadkaree S, Pandian V, Best SA, Motz K, Allen C, Kim Y, Akst LM, Hillel AT. Laryngotracheal stenosis: Risk factors for tracheostomy dependence and dilation interval. Otolaryngol Head Neck Surg. 2017;156:321-8. PMID: 28112014. PMC5348246.
Motz K, Yin LX, Samad I, Ding D, Murphy MK, Duvvuri MV, Hillel AT. Quantification of inflammatory markers in laryngotracheal stenosis. Otolaryngol Head Neck Surg. 2017;156:321-8. PMID: 28485188. PMC5593763.
Hillel AT, Gelbard A. Unleashing rapamycin on fibrosis. Oncotarget. 2015;6:15722-3. PMID: 26158293. PMC: 4599220.